57113-91-4Relevant articles and documents
Method for preparing 2-amino-3-methyl nitrobenzoate
-
, (2020/06/30)
The invention discloses a method for preparing methyl 2-amino-3-nitrobenzoate, which comprises the following steps: pumping a phthalimide solution and a sodium hypochlorite solution into a micro-reaction mixer, reacting, reacting with water in a tubular reactor to obtain methyl anthranilate, and continuously separating to obtain a crude product; pumping the methyl anthranilate crude product, an acetic anhydride solution and fuming nitric acid into a micro-channel reactor, mixing, reacting to obtain N-methyl nitrobenzoate, and continuously separating to obtain a crude product; pumping an N-methyl nitrobenzoate solution, concentrated sulfuric acid and water into a micro-channel reactor, mixing, and reacting to obtain a 2-amino-3-methyl nitrobenzoate crude product; recrystallizing the crude product in methanol to obtain a product, namely methyl 2-amino-3-nitrobenzoate; and the method is high in yield, good in safety and suitable for industrial production.
A 2 - ethoxy benzimidazole - 7 - carboxylic acid methyl ester
-
, (2018/05/24)
The invention discloses a synthesis method of 2-ethoxy benzimidazole-7-carboxylic acid methyl ester. The problem that an existing process is not high in content and is very low in yield is solved. According to the synthesis method, 3-nitryl phthalic acid is used as a raw material, rearrangement is performed in a water solution after methyl esterification, acylation and re-nitridation, then tin powder is adopted to perform reduction and loop closing so as to obtain the 2-ethoxy benzimidazole-7-carboxylic acid methyl ester. By the adoption of the synthesis method, produced impurities are very little, the content is high, and the yield is also high.
ANTI-MALIGNANT TUMOR AGENT COMPOSITION
-
Paragraph 0103, (2016/01/25)
To provide a satisfactory anticancer agent composition suppressing the growth of cancer (malignant tumor) reliably and hardly causing side effects, the present invention is directed to an anticancer agent composition including the following agents as active ingredient; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.